Cargando…

Repair of Mybpc3 mRNA by 5′-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy

RNA trans-splicing has been explored as a therapeutic option for a variety of genetic diseases, but not for cardiac genetic disease. Hypertrophic cardiomyopathy (HCM) is an autosomal-dominant disease, characterized by left ventricular hypertrophy (LVH) and diastolic dysfunction. MYBPC3, encoding car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mearini, Giulia, Stimpel, Doreen, Krämer, Elisabeth, Geertz, Birgit, Braren, Ingke, Gedicke-Hornung, Christina, Précigout, Guillaume, Müller, Oliver J, Katus, Hugo A, Eschenhagen, Thomas, Voit, Thomas, Garcia, Luis, Lorain, Stéphanie, Carrier, Lucie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731888/ https://www.ncbi.nlm.nih.gov/pubmed/23820890 http://dx.doi.org/10.1038/mtna.2013.31

Ejemplares similares

Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice
por: Gedicke-Hornung, Christina, et al.
Publicado: (2013)

Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes
por: Prondzynski, Maksymilian, et al.
Publicado: (2017)

Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches
por: Lorain, Stéphanie, et al.
Publicado: (2013)

Increased myofilament Ca(2+) sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice
por: Fraysse, Bodvaël, et al.
Publicado: (2012)

Epigallocatechin-3-Gallate Accelerates Relaxation and Ca(2+) Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice
por: Friedrich, Felix W., et al.
Publicado: (2016)

Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene
por: Ehlermann, Philipp, et al.
Publicado: (2008)

An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy
por: Tudurachi, Bogdan-Sorin, et al.
Publicado: (2023)

Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy
por: Schlossarek, Saskia, et al.
Publicado: (2014)

Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue
por: Dutsch, Alexander, et al.
Publicado: (2019)

Repair of Rhodopsin mRNA by Spliceosome-Mediated RNA Trans-Splicing: A New Approach for Autosomal Dominant Retinitis Pigmentosa
por: Berger, Adeline, et al.
Publicado: (2015)

Familial hypertrophic cardiomyopathy associated with a new mutation in gene MYBPC3
por: Aurensanz Clemente, Esther, et al.
Publicado: (2017)

Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy
por: Suay-Corredera, Carmen, et al.
Publicado: (2021)

Transcriptome Analysis of Cardiac Hypertrophic Growth in MYBPC3-Null Mice Suggests Early Responders in Hypertrophic Remodeling
por: Farrell, Emily, et al.
Publicado: (2018)

I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model
por: Friedrich, Felix W., et al.
Publicado: (2015)

Force and Calcium Transients Analysis in Human Engineered Heart Tissues Reveals Positive Force-Frequency Relation at Physiological Frequency
por: Saleem, Umber, et al.
Publicado: (2020)

Autosomal Recessive Transmission of MYBPC3 Mutation Results in Malignant Phenotype of Hypertrophic Cardiomyopathy
por: Wang, Yilu, et al.
Publicado: (2013)

The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy
por: Jørgenrud, Benedicte, et al.
Publicado: (2015)

Fatal neonatal hypertrophic cardiomyopathy caused by compound heterozygous truncating MYBPC3 mutation
por: Alsters, S., et al.
Publicado: (2019)

Myocardial Deformation Analysis in MYBPC3 and MYH7 Related Sarcomeric Hypertrophic Cardiomyopathy—The Graz Hypertrophic Cardiomyopathy Registry
por: Höller, Viktoria, et al.
Publicado: (2021)

Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing
por: Trochet, Delphine, et al.
Publicado: (2016)

MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy
por: McNamara, James W., et al.
Publicado: (2017)

Reevaluation of the South Asian MYBPC3(Δ25bp) Intronic Deletion in Hypertrophic Cardiomyopathy
por: Harper, Andrew R., et al.
Publicado: (2020)

Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers
por: Adalsteinsdottir, Berglind, et al.
Publicado: (2020)

Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy
por: Helms, Adam S., et al.
Publicado: (2020)

Identification of an elusive spliceogenic MYBPC3 variant in an otherwise genotype-negative hypertrophic cardiomyopathy pedigree
por: Torrado, Mario, et al.
Publicado: (2022)

Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants
por: Jansen, Mark, et al.
Publicado: (2023)

Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes—a systematic review
por: Eschenhagen, Thomas, et al.
Publicado: (2018)

Piezo2 is not an indispensable mechanosensor in murine cardiomyocytes
por: Kloth, Benjamin, et al.
Publicado: (2022)

Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy
por: Caiazza, Martina, et al.
Publicado: (2020)

Description of a Cohort with a New Truncating MYBPC3 Variant for Hypertrophic Cardiomyopathy in Northern Spain
por: Fernández Suárez, Natalia, et al.
Publicado: (2023)

A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy
por: Ni, Erru, et al.
Publicado: (2023)

Screening Mutations of MYBPC3 in 114 Unrelated Patients with Hypertrophic Cardiomyopathy by Targeted Capture and Next-generation Sequencing
por: Liu, Xuxia, et al.
Publicado: (2015)

Analysis of Contractile Function of Permeabilized Human Hypertrophic Cardiomyopathy Multicellular Heart Tissue
por: Kresin, Nico, et al.
Publicado: (2019)

Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations
por: Pei, J., et al.
Publicado: (2021)

Generation of two iPSC lines from hypertrophic cardiomyopathy patients carrying MYBPC3 and PRKAG2 variants
por: Manhas, Amit, et al.
Publicado: (2022)

A Novel Loss-of-function Mutation in MYBPC3 Causes Familial Hypertrophic Cardiomyopathy with Extreme Intrafamilial Phenotypic Heterogeneity
por: Peng, Y, et al.
Publicado: (2023)

Presence of known feline ALMS1 and MYBPC3 variants in a diverse cohort of cats with hypertrophic cardiomyopathy in Japan
por: Akiyama, Noriyoshi, et al.
Publicado: (2023)

Homozygous missense MYBPC3 Pro873His mutation associated with increased risk for heart failure development in hypertrophic cardiomyopathy
por: Kissopoulou, Antheia, et al.
Publicado: (2018)

CMR derived left ventricular septal convexity in carriers of the hypertrophic cardiomyopathy-causing MYBPC3-Q1061X mutation
por: Tarkiainen, Mika, et al.
Publicado: (2019)

Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation
por: Thompson, Andrea D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ohjgnamn226f90gtoctgcipehf